Crossmark

Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function

Crossref DOI link: https://doi.org/10.1038/s41380-017-0015-z

Published Online: 2017-12-21

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Joffe, Max E.

Santiago, Chiaki I.

Engers, Julie L.

Lindsley, Craig W.

Conn, P. Jeffrey
License Information

Text and Data Mining valid from 2017-12-21
More Information

Article History

Received: 20 July 2017

Revised: 8 October 2017

Accepted: 1 November 2017

First Online: 21 December 2017

Compliance with ethical standards

:

: C.W.L. has been funded by the NIH, Johnson and Johnson, Bristol-Myers Squibb, AstraZeneca, Michael J. Fox Foundation, as well as Seaside Therapeutics. He has consulted for AbbVie and received compensation. P.J.C. has been funded by NIH, AstraZeneca, Bristol-Myers Squibb, Michael J. Fox Foundation, Dystonia Medical Research Foundation, CHDI Foundation, and Thome Memorial Foundation. Over the past 3 years he has served on the Scientific Advisory Boards for Michael J. Fox Foundation, Stanley Center for Psychiatric Research Broad Institute, Karuna Pharmaceuticals, Lieber Institute for Brain Development, Clinical Mechanism and Proof of Concept Consortium, and Neurobiology Foundation for Schizophrenia and Bipolar Disorder. C.W.L. and P.J.C. are inventors on patents that protect different classes of metabotropic glutamate allosteric modulators. M.E.J., C.I.S., and J.L.E. declare no conflict of interest.